AMY-109 | H1009/L395-F1974m [2
AMY109 is a long-acting monoclonal antibody that blocks IL-8 recycling [4
]. It was designed to reduce levels of IL-8 in endometriosis lesions, in which excessive IL-8 has been identified as a driving factor in promoting inflammation and fibrosis [1
]. AMY109 is proposed as a potential disease-modifying treatment for endometriosis.
AMY109 is engineered to bind IL-8 in a pH-dependent manner. In the acidic conditions within the endosome, the antibody-IL-8 mmune complex dissociates; the free antibody is re-cycled and the IL-8 is trafficked to the lysosome for degradation.